Metal complexes are extensively used for cancer therapy. The multiple variables available
for tuning (metal, ligand, and metal–ligand interaction) offer unique opportunities for drug …

Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various
cancers. However, they have some limitations including poor selectivity and toxicity towards …

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

The platinum derivative cis-diamminedichloroplatinum (II), best known as cisplatin, is
currently employed for the clinical management of patients affected by testicular, ovarian …

As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of
the metal, its oxidation state, the types and number of coordinated ligands and the …

Platinum-based drugs, and in particular cis-diamminedichloroplatinum (II)(best known as
cisplatin), are employed for the treatment of a wide array of solid malignancies, including …

Chemoresistance is a central cause for the tumor management failure. Cancer cells disrupt
the redox homeostasis through reactive oxygen species (ROS) regulatory mechanisms …

In the last decades, the number of patients receiving chemotherapy has considerably
increased. Given the toxicity of cytotoxic agents to humans (not only for patients but also for …

Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design
of new drugs. This has, for instance, led to the clinical application of chemotherapeutic …